OQROSign up free
Insider trade

Lipocine (LPCN): Director received 1,764 units

John W. Higuchi, Director at Lipocine, reported a grant / award of 1,764 units.

1,764
Derivative units · @ $2.19
Traded
Jun 3, 2026
Filed
Jun 4, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Apr 6, 2026Insider · 2 peopleInsiders: 2 purchases (~$303K)
  2. Apr 7, 2026Insider · 9 days before an 8-KDirector purchased ~$81K of LPCN shares in the open market
  3. Apr 16, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On April 16, 2026, Spyros Papapetropoulos informed the Board of Directors (the “Board”) of Lipocine Inc. (the “Company”) that he resigned as a member of the Board effective immediately.”
  4. May 7, 2026Company filing · Form 8-K · ResultsReported its results
  5. Jun 3, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers As noted below, on June 3, 2026, the shareholders of Lipocine Inc. (the “Company”) approved the Sixth Amended and Restated 2014 Stock and Incentive Plan (the “2014 Plan”).”

What came next

  1. Aug 3, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On August 3, 2026, the Board of Directors of the Company expanded the Board of Directors to five members and appointed Michael Grissinger as a director, effective immediately.”
  2. Aug 3, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On August 18, 2026, the Board of Directors (the “Board”) of the Company appointed Michael Grissinger to serve as a member of the Compensation Committee of the Board.”
  3. Aug 4, 2026Company filing · Form 8-K · ResultsReported its results
  4. Sep 28, 2026InsiderDirector purchased ~$27K of LPCN shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Lipocine

For Lipocine, OQRO holds 5 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its LPCN page.

Other recent filings by John W. Higuchi, Director

The full history of John W. Higuchi, Director is on the profile page.

How this filing works

Explore the data

Other disclosures at Lipocine

Everything OQRO holds on this company is on its LPCN page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Sign up freeAlready have an account? Log in

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data